Medical Cannabis
Anvisa approves cannabis cultivation for medical purposes
Rapportert av AI Bilde generert av AI
The National Health Surveillance Agency (Anvisa) approved, on January 28, 2026, resolutions allowing cannabis cultivation for health treatments and research, along with new administration routes and plant imports. This step marks progress in the national production chain, easing access to plant-derived medicines. The changes broaden options for patients with severe illnesses while upholding strict restrictions.
A comprehensive analysis of over 2,500 studies shows that medical cannabis has strong evidence for only a few specific uses, despite widespread public belief in its broader effectiveness. Led by UCLA Health researchers, the review highlights gaps between perceptions and scientific proof for conditions like chronic pain and anxiety. It also identifies potential risks, particularly for adolescents and daily users.